The clinical use of the quantitative EEG (QEEG) from the pioneering work of John has received a new impetus thanks to new neuroimaging techniques and the possibility of using a number of normative databases both of normal subjects and of subjects with definite pathologies. In this direction, the term personalized medicine is becoming more and more common, a medical procedure that separates patients into different groups based on their predicted response to the quantitative EEG. This has allowed the study of single subjects and to customize health care, with decisions and treatments tailored to each individual patient, as well as improvement of knowledge of the pathophysiological mechanisms of specific diseases. This review article will present the most recent evidence in the field of developmental neuropsychiatric disorders obtained from the application of quantitative EEG both in clinical group studies (attention deficit hyperactivity disorder, developmental dyslexia, oppositional defiant disorder) and in individual case studies not yet published.
Keywords: QEEG; atomoxetine; developmental dyslexia; methylphenidate; micrography; oppositional defiant disorder; quantitative EEG; reading delay.